Shawn O'Brien

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.

Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.

Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.

SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer.

Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.

Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.

Profectus BioSciences, Inc. engages in the design and development of preventive and therapeutic vaccines. It develops novel vaccines for the prevention and treatment of infectious diseases and related cancers. The company’s vaccines are based on its proprietary VesiculoVax and GeneVax vaccine delivery platforms. The company was founded by Robert Charles Gallo, William A. Blattner, and Robert R. Redfield in 2003 and is headquartered in Baltimore, MD.

Alto Pharmaceuticals Ltd. Develops and commercialize products for maintaining a healthy lifestyle and improving quality of life. The firm’s area of interest includes dermatology and skin care, as well as post surgical support. The company was founded by Joan Chypyha in 2008 and is headquartered in Oakridges, Canada.